SEATTLE: Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it.
However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.
If successful, they will be in a position to command premium prices and tap the existing opportunity. A lot of drugs have failed in Phase III stage thus putting a greater impact on the Alzheimer’s disease drug market, claims the report…